Community Investing Ideas

Global Weekly Picks

CA$5.25
FV
9.3% undervalued intrinsic discount
770
users have viewed this narrative
3users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AU$0.4
FV
27.5% undervalued intrinsic discount
23.43%
Revenue growth p.a.
1.9k
users have viewed this narrative
5users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
US$433
19.2% undervalued intrinsic discount
Fair Value
Revenue
23.53% p.a.
Profit Margin
30.86%
Future PE
20.78x
Price in 2031
US$623.99
US$280
6.1% undervalued intrinsic discount
Fair Value
Revenue
11.71% p.a.
Profit Margin
10.14%
Future PE
36.93x
Price in 2031
US$411.54
US$173.02
84.8% undervalued intrinsic discount
Fair Value
Revenue
36.3% p.a.
Profit Margin
10%
Future PE
60x
Price in 2030
US$242.66
US$220
37.2% undervalued intrinsic discount
Fair Value
Revenue
9.64% p.a.
Profit Margin
14.22%
Future PE
10.42x
Price in 2036
US$512.69
ELTX logo
Elicio Therapeutics

Very Bullish

98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more

View narrative
US$100
89.7% undervalued intrinsic discount
Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2031
US$140.1